Avenue Biosciences
Founded 2023 · 3 known investors
Avenue Biosciences operates a platform that engineers N-terminal signal peptides to modulate the secretory pathway and improve protein yield, combining high-throughput chemistry, synthetic biology, and machine learning. It targets therapeutic and biotechnology developers, optimizing expression across mammalian protein production systems including recombinant protein therapies, biosimilars, and cell and gene therapies.
AI & Machine LearningBiotechDeep Tech
Investors · 3
Frequently asked questions
- What does Avenue Biosciences do?
- Avenue Biosciences operates a platform that engineers N-terminal signal peptides to modulate the secretory pathway and improve protein yield, combining high-throughput chemistry, synthetic biology, and machine learning. It targets therapeutic and biotechnology developers, optimizing expression across mammalian protein production systems including recombinant protein therapies, biosimilars, and cell and gene therapies.
- Who are Avenue Biosciences's investors?
- Avenue Biosciences's investors include Balnord Sp. z o.o., Inventure, Voima Ventures.